TheraRadar
← Back
Data updated: Mar 29, 2026

OMNIVIUM PHARMS

CardiovascularMetabolic
Pharma

OMNIVIUM PHARMS is a pharmaceutical company focused on Cardiovascular, Metabolic. Key products include NUMBRINO.

1993
Since
7
Drugs
-
Trials
78
Approved (2yr)

Key Drugs

NUMBRINO
cocaine hydrochloride
Voltage-gated sodium channels 1 indications · 2020

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

GLYCOPYRROLATE 2026-02-10
Labeling
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-02-09
Labeling
GLYCOPYRROLATE 2026-02-06
Labeling
OLANZAPINE 2026-01-23
OLANZAPINE 2026-01-22
Labeling
GLYCOPYRROLATE 2026-01-19
Labeling
GLYCOPYRROLATE 2026-01-19
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 67%
2 drugs
Metabolic 33%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Merck big-pharma
Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Cardiovascular, Metabolic
Bayer big-pharma
Cardiovascular, Metabolic
B BRAUN specialty
Metabolic, Cardiovascular
AstraZeneca big-pharma
Cardiovascular, Metabolic